跳至主要内容
临床试验/PACTR202204601902304
PACTR202204601902304Other3 期

Evaluation of the Effect of Intravitreal Anti-vascular Endothelial Growth Factor versus Medical Treatment in Acute Central Serous Chorioretinopathy

Suez Canal University Hospital0 个研究点目标入组 45 人开始时间: 2022年4月4日最近更新:
适应症

试验速览

阶段
3 期
状态
Other
发起方
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19 Year(s) 至 44 Year(s)(—)
性别
All

入选标准

  • Patients older than 18 years old, with presence of serous detachment of neurosensory retina on optical coherence tomography angiography (OCTA), evidence of fluorescent leakage on fundus fluorescein angiography (FFA) and symptom duration less than 3 months will be enrolled in the study.

排除标准

  • Patients with chronic CSCR, secondary choroidal neovascularization, other eye diseases such as AMD, polypoidal choroidal vasculopathy, glaucoma, or ocular trauma; or having history of systemic steroid usage before the onset of the clinical symptoms will be excluded from the study.

研究者

发起方
Suez Canal University Hospital

相似试验